Status | Study |
Completed |
Study Name: Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative Disorder Condition: Leukemia Date: 2012-01-13 Interventions: Genetic: RNA analysis Genetic: reverse tra |
Completed |
Study Name: MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Condition: Accelerated Phase Chronic Myelogenous Leukemia Acute Leukemias of Ambiguous Lineage Date: 2010-10-29 Interventions: Drug: Akt inhibitor MK2206 Giv |
Recruiting |
Study Name: Study of Blood Samples From Newborns With Down Syndrome Condition: Leukemia Date: 2009-08-13 Interventions: Genetic: DNA analysis Genetic: RNA analysi |
Withdrawn |
Study Name: Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder Condition: Leukemia Date: 2006-12-11 Interventions: Drug: cytarabine Given subcuta |
Completed |
Study Name: Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Condition: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome Acute Date: 2006-05-02 Interventions: Radiation: total-body irradiation |
Active, not recruiting |
Study Name: Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies Condition: Acute Myeloid Leukemia/Transient Myeloproliferative Disorder Acute Undifferentiated Leukemia Date: 2001-04-10 Interventions: Drug: fludarabine phosphate Gi |